Literature DB >> 26851004

Potential Dual Role of Activating Transcription Factor 3 in Colorectal Cancer.

Xiaojing Jiang1, Kui-Jin Kim1, Taekyu Ha1, Seong-Ho Lee2.   

Abstract

BACKGROUND/AIM: Activating transcription factor 3 (ATF3) is a member of the ATF/CREB transcription factor family and has been proposed as a molecular target for cancer therapy. The present study was undertaken in order to investigate whether ATF3 influences cancer-related phenotypes in colorectal cancer.
MATERIALS AND METHODS: ATF3 was overexpressed in human colorectal cancer cells and the effects of ATF3 on apoptosis, cell cycle, cell migration and epithelial mesenchymal transition (EMT) were investigated. B-cell lymphoma-2 (Bcl-2) promoter was cloned and used for luciferase assay in cells transfected with control or ATF3 expression vector.
RESULTS: ATF3 down-regulated the expression of Bcl-2 and promoter activity of the Bcl-2 gene. ATF3 increased collective cell migration and expression of cluster of differentiation 44 (CD44) and decreased retinoblastoma (Rb) expression. In addition, ATF3 down-regulated EMT-inducing transcription factors and β-catenin.
CONCLUSION: ATF3 may play a dichotomous role in apoptosis and metastasis in human colorectal cancer cells. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Activating transcription factor 3; Bcl-2; apoptosis; colorectal cancer; migration

Mesh:

Substances:

Year:  2016        PMID: 26851004

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  Systematic review of the old and new concepts in the epithelial-mesenchymal transition of colorectal cancer.

Authors:  Simona Gurzu; Camelia Silveanu; Annamaria Fetyko; Vlad Butiurca; Zsolt Kovacs; Ioan Jung
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

2.  The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.

Authors:  My-Lan Kha; Lisa Hesse; Florian Deisinger; Bence Sipos; Christoph Röcken; Alexander Arlt; Susanne Sebens; Ole Helm; Heiner Schäfer
Journal:  Oncogene       Date:  2018-10-09       Impact factor: 9.867

3.  Cigarette smoke extract profoundly suppresses TNFα-mediated proinflammatory gene expression through upregulation of ATF3 in human coronary artery endothelial cells.

Authors:  Jack E Teasdale; Georgina G J Hazell; Alasdair M G Peachey; Graciela B Sala-Newby; Charles C T Hindmarch; Tristan R McKay; Mark Bond; Andrew C Newby; Stephen J White
Journal:  Sci Rep       Date:  2017-01-06       Impact factor: 4.379

4.  Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.

Authors:  Carmela De Marco; Carmelo Laudanna; Nicola Rinaldo; Duarte Mendes Oliveira; Maria Ravo; Alessandro Weisz; Michele Ceccarelli; Elvira Caira; Antonia Rizzuto; Pietro Zoppoli; Donatella Malanga; Giuseppe Viglietto
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

5.  A causal mediation model of ischemia reperfusion injury in the retina.

Authors:  Maha Soliman; Kalina Andreeva; Olfa Nasraoui; Nigel G F Cooper
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

6.  Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes.

Authors:  Miori Tanaka; Akari Sato; Yoshimi Kishimoto; Hideaki Mabashi-Asazuma; Kazuo Kondo; Kaoruko Iida
Journal:  Nutrients       Date:  2020-05-20       Impact factor: 5.717

7.  ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.

Authors:  Hao Tian; Fu-Ju Chou; Jing Tian; Yong Zhang; Bosen You; Chi-Ping Huang; Shuyuan Yeh; Yuanjie Niu; Chawnshang Chang
Journal:  J Exp Clin Cancer Res       Date:  2021-01-04

8.  ATF3 downmodulates its new targets IFI6 and IFI27 to suppress the growth and migration of tongue squamous cell carcinoma cells.

Authors:  Lin Xu; Tingjian Zu; Tao Li; Min Li; Jun Mi; Fuxiang Bai; Guanyi Liu; Jie Wen; Hui Li; Cord Brakebusch; Xuxia Wang; Xunwei Wu
Journal:  PLoS Genet       Date:  2021-02-04       Impact factor: 5.917

9.  Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel.

Authors:  Haitao Wang; Sen Guo; Seung-Jin Kim; Fangyuan Shao; Joshua Wing Kei Ho; Kuan Un Wong; Zhengqiang Miao; Dapeng Hao; Ming Zhao; Jun Xu; Jianming Zeng; Koon Ho Wong; Lijun Di; Ada Hang-Heng Wong; Xiaoling Xu; Chu-Xia Deng
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

10.  The mechanism of ATF3 repression of epithelial-mesenchymal transition and suppression of cell viability in cholangiocarcinoma via p53 signal pathway.

Authors:  Zhen You; Jingchang Xu; Bei Li; Hui Ye; Liping Chen; Yang Liu; Xianze Xiong
Journal:  J Cell Mol Med       Date:  2019-01-16       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.